Founded only a year ago, cancer drug firm Cleave Biosciences attracted a whopping $42 million in a Series A financing, expected to be disclosed Tuesday, to push its lead programs into the clinic.Founded only a year ago, cancer drug firm Cleave Biosciences attracted a whopping $42 million in a Series A financing, expected to be disclosed Tuesday, to push its lead programs into the clinic.